GlassScriptPhysician profile
Jon Michael Hain
NPI 1497720288
$3,376.93
in general payments reported to CMS, 2019-2025
20 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $123 · 2021: $309 · 2022: $650 · 2023: $508 · 2024: $651 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,171.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,037.53 | 2019-2025 | |
| Janssen Biotech, INC. | $577.83 | 2020-2025 | Stelara, Tremfya, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $477.21 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Scientific Affairs, LLC | $237.16 | 2024-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.58 | 2022-2025 | Xifaxan |
| Vioptix INC | $173.29 | 2021-2022 | |
| Celgene Corporation | $129.03 | 2021-2023 | Zeposia |
| Ferring Pharmaceuticals INC. | $108.40 | 2020-2023 | Rebyota |
| Lilly USA, LLC | $95.08 | 2023-2024 | Omvoh |
| Merck Sharp & Dohme LLC | $60.82 | 2022 | |
| Pfizer INC. | $50.30 | 2022 | |
| Shire North American Group INC | $36.70 | 2019 | |
| Hologic Sales and Service, LLC | $35.09 | 2025 | Coolseal Generator |
| Amgen INC. | $26.84 | 2023 | Avsola, Amjevita |
| Smith+Nephew, INC. | $26.20 | 2024 | Pico 7 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $25.05 | 2024 | Hyrimoz |
| Medtronic, INC. | $23.32 | 2024 | Eea |
| Daiichi Sankyo INC. | $18.02 | 2020 | |
| Convatec INC. | $14.47 | 2022 | |
| Aimmune Therapeutics, INC. | $14.01 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Hain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.